SCHEMBL1694342

SCHEMBL1694342

CCOC(=O)C(=O)CC(=O)C1CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.44
MAPT P10636 4/20 0.42
RAB9A P51151 1/20 0.41
RECQL P46063 1/20 0.39
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
SOAT1 P35610 1/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
ALOX15 P16050 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HIF1A Q16665 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3388901 0.92 GAA (0.41) GAAMAPTRAB9AMGAMSI
SCHEMBL3993142 0.92 ALDH1A1 (0.44) GAAMAPTRAB9AALDH1A1POLB
SCHEMBL27006521 0.91 GAA (0.42) GAAMAPTRAB9ARECQLALDH1A1
SCHEMBL27130827 0.91 GAA (0.42) GAAMAPTRAB9ARECQLALDH1A1
SCHEMBL24512542 0.91 ALDH1A1 (0.46) GAAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL1739339 0.91 ALDH1A1 (0.46) GAAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL28548541 0.88 GAA (0.37) GAAMAPTRAB9ARECQLALDH1A1
SCHEMBL28548543 0.88 GAA (0.37) GAAMAPTRAB9ARECQLALDH1A1
SCHEMBL15566866 0.88 ALDH1A1 (0.40) GAAMAPTRAB9ARECQLALDH1A1
SCHEMBL15566435 0.85 GAA (0.37) GAAMAPTRAB9ARECQLMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025105858-A1 HETEROARYL-DERIVATIVE COMPOUND AND USE THEREOF (주)신테카바이오 2025-05-22 WO disclosed
EP-4543890-A1 USP1 INHIBITORS AND USES THEREOF Forma Therapeutics, Inc. (US) 2025-04-30 EP disclosed
CN-119731178-A USP1 inhibitors and uses thereof 福马治疗有限公司 2025-03-28 CN disclosed
CN-115151550-B External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof 桑福德·伯纳姆·普雷比医学发现研究所 2024-11-22 CN disclosed
WO-2024206628-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN NALO THERAPEUTICS (US) 2024-10-03 WO disclosed
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2024-09-19 US disclosed
CN-118434737-A Aromatic heterobicyclic compounds and antiviral uses thereof 苏州爱科百发生物医药技术有限公司 2024-08-02 CN disclosed
EP-4334295-A2 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuoscience, Inc. (US) 2024-03-13 EP disclosed
CN-117597333-A Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use 维吉尔神经科学股份有限公司 2024-02-23 CN disclosed
WO-2023250084-A1 USP1 INHIBITORS AND USES THEREOF FORMA THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 WO disclosed
EP-1122242-B1 CYANOPHENYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-01-16 EP disclosed
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2005-11-10 US disclosed
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-16 US disclosed
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-09 US disclosed
US-20040010037-A1 Cyanophenyl derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. 2004-01-15 US disclosed
US-6673799-B1 INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-01-06 US disclosed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003093250-A2 POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR PHARMACIA & UPJOHN COMPANY (US) 2003-11-13 WO disclosed
EP-1122242-A1 CYANOPHENYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2001-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 GAA 2909/4885MAPT 1550/4885RAB9A 1449/4885
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 GAA 2909/4885MAPT 1550/4885RAB9A 1449/4885
US-20040010037-A1 Cyanophenyl derivative BPHL, AR, KLK3 GAA 4258/4885MAPT 4216/4885RAB9A 4547/4885
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 GAA 1670/4885MAPT 681/4885RAB9A 2702/4885
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 GAA 2909/4885MAPT 1550/4885RAB9A 1449/4885
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA7, CHRNA1, CHRNA5 GAA 2148/4885MAPT 1395/4885RAB9A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.